Genome-Wide Epigenomic Analyses in Patients With Nociceptive and Neuropathic Chronic Pain Subtypes Reveals Alterations in Methylation of Genes Involved in the Neuro-Musculoskeletal System.


Journal

The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657

Informations de publication

Date de publication:
02 2022
Historique:
received: 03 04 2021
revised: 25 08 2021
accepted: 11 09 2021
pubmed: 22 9 2021
medline: 22 3 2022
entrez: 21 9 2021
Statut: ppublish

Résumé

Nociceptive pain involves the activation of nociceptors without damage to the nervous system, whereas neuropathic pain is related to an alteration in the central or peripheral nervous system. Chronic pain itself and the transition from acute to chronic pain may be epigenetically controlled. In this cross-sectional study, a genome-wide DNA methylation analysis was performed using the blood DNA reduced representation bisulfite sequencing (RRBS) technique. Three prospective cohorts including 20 healthy controls (CTL), 18 patients with chronic nociceptive pain (NOCI), and 19 patients with chronic neuropathic pain (NEURO) were compared at both the single CpG and differentially methylated region (DMR) levels. Genes with DMRs were seen in the NOCI and NEURO groups belonged to the neuro-musculoskeletal system and differed between NOCI and NEURO patients. Our results demonstrate that the epigenetic disturbances accompanying nociceptive pain are very different from those accompanying neuropathic pain. In the former, among others, the epigenetic disturbance observed would affect the function of the opioid analgesic system, whereas in the latter it would affect that of the GABAergic reward system. This study presents biological findings that help to characterize NOCI- and NEURO-affected pathways and opens the possibility of developing epigenetic diagnostic assays. PERSPECTIVE: Our results help to explain the various biological pathways modifications underlying the different clinical manifestations of nociceptive and neuropathic pains. Furthermore, the new targets identified in our study might help to discover more specific treatments for nociceptive or neuropathic pains.

Identifiants

pubmed: 34547430
pii: S1526-5900(21)00332-1
doi: 10.1016/j.jpain.2021.09.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

326-336

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Ludwig Stenz (L)

Department of Genetic Medicine and Development, Geneva University, Medicine Faculty, Geneva, Switzerland.

Joane Le Carré (JL)

Institute for Research in Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Medical Research, Clinique romande de réadaptation, Sion, Switzerland.

François Luthi (F)

Institute for Research in Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Musculoskeletal Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Physical Medicine and Rehabilitation, Orthopaedic Hospital, Lausanne University Hospital, Lausanne, Switzerland.

Philippe Vuistiner (P)

Institute for Research in Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Medical Research, Clinique romande de réadaptation, Sion, Switzerland.

Cyrille Burrus (C)

Institute for Research in Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Musculoskeletal Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland.

Ariane Paoloni-Giacobino (A)

Department of Genetic Medicine and Development, Geneva University, Medicine Faculty, Geneva, Switzerland.

Bertrand Léger (B)

Institute for Research in Rehabilitation, Clinique romande de réadaptation, Sion, Switzerland; Department of Medical Research, Clinique romande de réadaptation, Sion, Switzerland. Electronic address: Bertrand.Leger@crr-suva.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH